Key Points Novo Nordisk just admitted that its CagriSema weight loss drug isn't obviously better than Zepbound. This is a win for Eli Lilly, and a loss for Novo Nordisk. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) is taking it on the chin this morning, after revealing the latest clinical trial results for weight loss using its CagriSema drug (a 50-50 mix of amylin analog cagrilintide and Novo's glucagon-like peptide-1 (GLP-1) receptor agonist). After an 84-week trial, Novo reported that its patients achieved 23% weight loss with the drug. That sounds like pretty good news, but investors don't seem to like the number -- and as of 10:10 a.m. ET, Novo Nordisk stock is down 14.8%. Will AI create the world's first trillionaire?
Главную мысль мы показываем публично. Создайте бесплатный аккаунт, чтобы читать статью полностью, сохранять ее, обсуждать и связывать с рынками и OSINT-контекстом.